Compare RKLB & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKLB | ONC |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 40.6B |
| IPO Year | 2020 | 2015 |
| Metric | RKLB | ONC |
|---|---|---|
| Price | $70.53 | $358.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 28 |
| Target Price | $109.37 | ★ $432.80 |
| AVG Volume (30 Days) | ★ 16.1M | 320.8K |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.63 | ★ 140.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | ★ $601,799,000.00 | $238,387,000.00 |
| Revenue This Year | $59.24 | $26.33 |
| Revenue Next Year | $42.18 | $14.36 |
| P/E Ratio | ★ N/A | $1,196.77 |
| Revenue Growth | 37.96 | ★ 22179.16 |
| 52 Week Low | $37.57 | $253.95 |
| 52 Week High | $150.85 | $385.22 |
| Indicator | RKLB | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 60.26 |
| Support Level | $64.94 | $327.01 |
| Resistance Level | $77.33 | $380.00 |
| Average True Range (ATR) | 3.29 | 6.86 |
| MACD | 0.80 | 0.75 |
| Stochastic Oscillator | 64.00 | 87.88 |
Rocket Lab Corp is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, and rest of the world and earns key revenue from the United States.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.